Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from NexGel Inc ( (NXGL) ).
On April 27, 2026, NEXGEL’s board appointed veteran finance executive Ian Blackman as Chief Financial Officer, succeeding interim CFO Adam E. Drapczuk III, who will continue as a financial consultant. Blackman’s compensation package includes a $250,000 base salary, performance-based cash bonuses tied to 2026 EBITDA targets, and stock options with change-in-control and severance protections, underscoring NEXGEL’s push to strengthen its finance function as it advances the planned acquisition and integration of Celularity’s regenerative biomaterial product portfolio and scales its growing consumer and healthcare business.
The most recent analyst rating on (NXGL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
Spark’s Take on NXGL Stock
According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, negative cash flow, and inconsistent recent revenue) and bearish technicals (trading below major moving averages). These are partially offset by the latest earnings-call guidance pointing to a potentially large step-up in scale and a near-term path to EBITDA profitability, though financing/dilution and execution risks remain material.
To see Spark’s full report on NXGL stock, click here.
More about NexGel Inc
NEXGEL, Inc. is a Langhorne, Pa.-based provider of healthcare, beauty and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogel technologies for healthcare and consumer applications. The company markets brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm and Silly George, and maintains strategic contract manufacturing relationships with leading consumer healthcare companies.
On April 27, 2026, NEXGEL’s board appointed veteran finance executive Ian Blackman as Chief Financial Officer, succeeding interim CFO Adam E. Drapczuk III, who will continue as a financial consultant. Blackman’s compensation package includes a $250,000 base salary, performance-based cash bonuses tied to 2026 EBITDA targets, and stock options with change-in-control and severance protections, underscoring NEXGEL’s push to strengthen its finance function as it advances the planned acquisition and integration of Celularity’s regenerative biomaterial product portfolio and scales its growing consumer and healthcare business.
Average Trading Volume: 368,887
Technical Sentiment Signal: Sell
Current Market Cap: $6.64M
Learn more about NXGL stock on TipRanks’ Stock Analysis page.